Primary cutaneous follicle centre lymphoma Primary Prevention

Primary cutaneous follicle centre lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Primary cutaneous follicle centre lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Primary cutaneous follicle centre lymphoma Primary Prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma Primary Prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Primary cutaneous follicle centre lymphoma Primary Prevention
CDC on Primary cutaneous follicle centre lymphoma Primary Prevention
Primary cutaneous follicle centre lymphoma Primary Prevention in the news
Blogs on Primary cutaneous follicle centre lymphoma Primary Prevention
Directions to Hospitals Treating Splenic marginal zone lymphoma
Risk calculators and risk factors for Primary cutaneous follicle centre lymphoma Primary Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2] Soroush Seifirad, M.D.[3]

Overview

There are no established measures for the primary prevention of primary cutaneous follicle centre lymphoma.

OR

There are no available vaccines against primary cutaneous follicle centre lymphoma.

OR

Effective measures for the primary prevention of primary cutaneous follicle centre lymphoma include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent primary cutaneous follicle centre lymphoma. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Primary Prevention

There are no established measures for the primary prevention of primary cutaneous follicle centre lymphoma.

OR

There are no available vaccines against primary cutaneous follicle centre lymphoma.

OR

Effective measures for the primary prevention of primary cutaneous follicle centre lymphoma include:

• [Measure1]
• [Measure2]
• [Measure3]

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent primary cutaneous follicle centre lymphoma. Other primary prevention strategies include:

• [Strategy 1]
• [Strategy 2]
• [Strategy 3]